Version for print Main / Articles / Safety assessment of using incobotulinumtoxin A in the treatment of concomitant strabismus in children

Safety assessment of using incobotulinumtoxin A in the treatment of concomitant strabismus in children

Scopus

Abstract

DOI: 10.32364/2311-7729-2025-25-3-4

V.S. Cha¹, E.E. Sidorenko^1,2, E.I. Sidorenko¹, D.V. Miguel^1,2, E.V. Ermolaeva², V.E. Loskutova^2, A.D. Stepashkina³

¹N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation

²Research Practical Center for Children's Specialized Medical Care, Moscow, Russian Federation

³Novosibirsk State Medical University, Novosibirsk, Russian Federation

Background: strabismus is a significant pathology that presents both aesthetic and functional challenges. Chemodenervation with botulinum toxin type A (BoNT-A) is a well-established treatment for strabismus that has been in use since the 1980s. The technique of chemodenervation continues to evolve, with various new administration methods and formulations, all of which are based on BoNT-A. Of particular interest is a modification purified of immunogenic complexing proteins, which reduces the risk of sensitization and diminishes the likelihood of decreased efficacy with repeated injections. In the scientific literature, this formulation is commonly referred to as incobotulinumtoxin A. However, there is a paucity of data regarding the use of incobotulinumtoxin A in ophthalmology, and associated risks remain unclear. This study describes the results of an atraumatic chemodenervation technique using a new-generation BoNT-A preparation.

Aim: to assess the efficacy and safety of an atraumatic method for the treatment of concomitant strabismus in children using incobotulinumtoxin A.

Patients and Methods: the study included 40 patients (80 eyes) aged 1 to 12 years with concomitant strabismus who underwent chemodenervation with incobotulinumtoxin A. Prior to chemodenervation, patients underwent an evaluation of their general somatic status and ophthalmological examination. An atraumatic forceps was used to access the extraocular muscles. The study was approved by the local Ethics Committee of the N.I. Pirogov Russian National Research Medical University.

Results: no adverse events in general health status or systemic function were observed. No complications requiring additional medical intervention occurred. The overall efficacy rate was 87.5%. Only transient adverse events were identified, including ptosis (36.84%), hypercorrection (28.07%), and subconjunctival hemorrhage (hyposphagma, 7.02%). These transient events did not impair patients' quality of life, did not require treatment, and resolved spontaneously within four weeks.

Conclusion: atraumatic chemodenervation using incobotulinumtoxin A injections is an effective and safe method for the correction of concomitant strabismus in children. The absence of systemic reactions and complications, short procedure duration (~5 minutes), and transient nature of adverse events confirm its suitability for pediatric ophthalmology.

Keywords: incobotulinumtoxin A, botulinum toxin type A, extraocular muscle pathology, concomitant strabismus, chemodenervation, transient ptosis, minimally invasive treatment.

For citation: Cha V.S., Sidorenko E.E., Sidorenko E.I., Miguel D.V., Ermolaeva E.V., Loskutova V.E., Stepashkina A.D. Safety assessment of using incobotulinumtoxin A in the treatment of concomitant strabismus in children. Russian Journal of Clinical Ophthalmology. 2025;25(3):185–190 (in Russ.). DOI: 10.32364/2311-7729-2025-25-3-4

About the authors:

Vasily S. Cha — postgraduate student at the Department of Ophthalmology of the Institute of Motherhood and Childhood, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0001-9224-3074

Evgeniy E. Sidorenko — Dr. Sc. (Med.), Professor of the Department of Ophthalmology at the Institute of Motherhood and Childhood, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-2177-5134

Evgeniy I. Sidorenko — corresponding member of the RAS, Dr. Sc. (Med.), Professor of the Department of Ophthalmology at the Institute of Motherhood and Childhood, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-9648-5625

Dmitry V. Miguel — Laboratory Assistant at the Institute of Motherhood and Childhood, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ophthalmologist of the Research Practical Center for Children's Specialized Medical Care; 38, Aviatorov str., Moscow, 119620, Russian Federation; ORCID iD 0000-0001-9055-3861

Elena V. Ermolaeva — Junior Researcher, Research Practical Center for Children's Specialized Medical Care; 38, Aviatorov str., Moscow, 119620, Russian Federation; ORCID iD 0000-0002-0124-9786

Viktoriya E. Loskutova — Junior Researcher, Research Practical Center for Children's Specialized Medical Care; 38, Aviatorov str., Moscow, 119620, Russian Federation; ORCID iD 0000-0001-5709-9871

Anastasia D. Stepashkina — student at the Pediatric Faculty, Novosibirsk State Medical University, Novosibirsk State Medical University; 52, Krasny Ave., Novosibirsk, 630091, Russian Federation; ORCID iD 0009-0007-0442-3851

Contact information: Vasily S. Cha, e-mail: Chavas6526@ya.ru

Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.

There is no conflict of interest.

Received 08.06.2025.

Revised 30.06.2025.

Accepted 23.07.2025.

References

1. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044–1049. DOI: 10.1016/s0161-6420(80)35127-0 2. Ефимова Е.Л. Применение ботулинического токсина типа А в лечении пациентов с различными видами косоглазия. Российская педиатрическая офтальмология. 2017;12(3):128–133. DOI: 10.18821/1993-1859-2017-12-3-153-162Efimova E.L. The use of botulinum toxin type A in the treatment of patients with various types of strabismus. Russian Pediatric Ophthalmology. 2017;12(3):128–133 (in Russ.). DOI: 10.18821/1993-1859-2017-12-3-153-162 3. Аветисов С.Э. Офтальмология: национальное руководство. Под ред. С.Э. Аветисова, Е.А. Егорова, Л.К. Мошетовой и др. М.: ГЭОТАР-Медиа; 2013.Ophthalmology: national guide. Avetisov S.E., Egorova E.A., Moshetova L.K. et al., eds. M.: GEOTAR-Media; 2013 (in Russ.). 4. Wan M.J., Mantagos I.S., Shah A.S. et al. Comparison of Botulinum Toxin with Surgery for the Treatment of Acute-Onset Comitant Esotropia in Children. Am J Ophthalmol. 2017;176:33–39. DOI: 10.1016/j.ajo.2016.12.024 5. Spencer R.F., McNeer K.W. Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alterations in orbital, singly innervated muscle fibers. Arch Ophthalmol. 1987;105(12):1703–1711. DOI: 10.1001/archopht.1987.01060120101035 6. Wagner R.S. Strabismus Surgery Following Botulinum Injection for Infantile Esotropia. J Pediatr Ophthalmol Strabismus. 2024;61(4):228. DOI: 10.3928/01913913-20240626-01 7. Rzany B., Flynn T.C., Schlöbe A. et al. Long-term results for incobotulinumtoxin A in the treatment of glabellar frown lines. Dermatol Surg. 2013;39(1):95–103. DOI: 10.1111/dsu.12008 8. Carruthers A., Carruthers J., Coleman W.P. et al. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxin A in the treatment of glabellar frown lines. Dermatol Surg. 2013;39(4):551–558. DOI: 10.1111/dsu.12100 9. Ramos V.F., Karp B.I., Lungu C. et al. Clinical Response to Incobotulinumtoxin A after Loss of Response to Onabotulinumtoxin A. Mov Disord Clin Pract. 2014;1(4):383–385. DOI: 10.1002/mdc3.12094 10. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®. Drugs R D. 2010;10:67–73. DOI: 10.2165/11584780-000000000-00000 11. Kerscher M., Wanitphakdeedecha R., Trindade De Almeida A. et al. Incobotulinumtoxin A: a highly purified botulinum neurotoxin type A. J Drugs Dermatol. 2019;18(1):72–78. PMID: 30681794 12. Panjwani N., O‘Keeffe R., Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J. 2008;1:153–166. DOI: 10.1504/TBJ.2008.018956 13. Frevert J. Xeomin is free from complexing proteins. Toxicon. 2009;54:697–701. DOI: 10.1016/j.toxicon.2009.03.010 14. Hefter H., Rosenthal D., Jansen A. et al. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. J Neurol. 2023;270(2):788–796. DOI: 10.1007/s00415-022-11395-2 15. Wissel J., Bensmail D., Ferreira J.J. et al. TOWER study investigators. Safety and efficacy of incobotulinumtoxin A doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017;88(14):1321–1328. DOI: 10.1212/WNL.0000000000003789 16. Albrecht P., Jansen A., Lee J.I. et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;1;92(1):e48–e54. DOI: 10.1212/WNL.0000000000006688 17. Lennerstrand G., Nordbø O.A., Tian S. et al. Treatment of strabismus and nystagmus with botulinum toxin type A. Acta Ophthalmol Scand. 1998;76(1):27–37. DOI: 10.1034/j.1600-0420.1998.760106.x 18. Magoon E.H., Scott A.B. Botulinum toxin chemo-denervation in infants and children. J Pediatr. 1987;110(5):719–722. DOI: 10.1016/s0022-3476(87)80009-4 19. Liu M., Lee H.C., Hertle R.W. et al. Retinal detachment from inadvertent intraocular injection of botulinum toxin A. Am J Ophthalmol. 2004;137(1):201–202. DOI: 10.1016/s0002-9394(03)00837-7 20. Heinen F., Kanovský P., Schroeder A.S. et al. Incobotulinumtoxin A for lower-limb spasticity in children and adolescents with cerebral palsy. J Pediatr Rehabil Med. 2021;14(2):183–197. DOI: 10.3233/PRM-210040

This work is licensed under a Creative Commons «Attribution» 4.0 License.

Read the article in PDF in Russian

Multimodal approach to studying the pred...

924

Features of ophthalmological manifestati...

1910

All articles